Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.